ZA202309774B - Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy - Google Patents

Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy

Info

Publication number
ZA202309774B
ZA202309774B ZA2023/09774A ZA202309774A ZA202309774B ZA 202309774 B ZA202309774 B ZA 202309774B ZA 2023/09774 A ZA2023/09774 A ZA 2023/09774A ZA 202309774 A ZA202309774 A ZA 202309774A ZA 202309774 B ZA202309774 B ZA 202309774B
Authority
ZA
South Africa
Prior art keywords
chemotherapeutics
combination
galectin
antibodies
cancer therapy
Prior art date
Application number
ZA2023/09774A
Other languages
English (en)
Inventor
Filipovic Aleksandra
Elenko Eric
Heather Paden
Christopher Korth
Original Assignee
Puretech Lyt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech Lyt Inc filed Critical Puretech Lyt Inc
Publication of ZA202309774B publication Critical patent/ZA202309774B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2023/09774A 2021-04-30 2023-10-19 Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy ZA202309774B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163182519P 2021-04-30 2021-04-30
US202163193381P 2021-05-26 2021-05-26
US202263313882P 2022-02-25 2022-02-25
PCT/US2022/027142 WO2022232653A1 (en) 2021-04-30 2022-04-29 Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy

Publications (1)

Publication Number Publication Date
ZA202309774B true ZA202309774B (en) 2024-12-18

Family

ID=83847357

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/09774A ZA202309774B (en) 2021-04-30 2023-10-19 Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy

Country Status (8)

Country Link
US (1) US20240182583A1 (https=)
EP (1) EP4329808A4 (https=)
JP (1) JP2024519449A (https=)
AU (1) AU2022264597A1 (https=)
CA (1) CA3217833A1 (https=)
IL (1) IL308020A (https=)
WO (1) WO2022232653A1 (https=)
ZA (1) ZA202309774B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020223704A1 (en) * 2019-05-01 2020-11-05 New York University Anti-galectin-9 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312910B1 (en) * 2017-10-27 2026-02-01 Univ New York Anti-galectin-9 antibodies and their uses
WO2020223704A1 (en) * 2019-05-01 2020-11-05 New York University Anti-galectin-9 antibodies and uses thereof
US20220332832A1 (en) * 2019-08-01 2022-10-20 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics

Also Published As

Publication number Publication date
EP4329808A4 (en) 2025-03-12
US20240182583A1 (en) 2024-06-06
IL308020A (en) 2023-12-01
JP2024519449A (ja) 2024-05-14
WO2022232653A1 (en) 2022-11-03
CA3217833A1 (en) 2022-11-03
AU2022264597A9 (en) 2023-11-16
EP4329808A1 (en) 2024-03-06
AU2022264597A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
Urun et al. Association of ABO blood group and risk of lung cancer in a multicenter study in Turkey
Pavlidis et al. A mini review on cancer of unknown primary site: a clinical puzzle for the oncologists
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
Song et al. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients
Zurleni et al. Conversion surgery for gastric cancer patients: a review
ZA202309774B (en) Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
Zhao et al. Clinicopathological characteristics and prognosis of proximal and distal gastric cancer during 1997–2017 in China National Cancer Center
Shu et al. Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients
Min et al. Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: a meta-analysis of randomized trials
Cho et al. Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer
RU2016112421A (ru) Протиоопухолевое средство и усилитель противоопухолевого эффекта
Chen et al. Palliative Gastrectomy versus Gastrojejunostomy for advanced Gastric cancer with outlet obstruction: a propensity score matching analysis
Lee et al. Indication of proximal gastrectomy for advanced proximal gastric cancer based on lymph node metastasis at the distal part of the stomach
ZA202309775B (en) Anti-galectin-9 antibodies and therapeutic uses thereof
Bath et al. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma
Selcukbiricik et al. Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy?
Chen et al. Treatment outcomes of locally advanced hypopharyngeal squamous cell carcinoma
MX2023010825A (es) Metodos para tratar el cancer con anticuerpos anti-ilt3.
Motoyama et al. Survival benefits of surgical resection in patients with recurrent biliary tract carcinoma
Huang et al. The use of chemotherapy in treating gastric cancers
Rades et al. The effect of low hemoglobin levels on outcomes of radiotherapy following microscopically complete resection of locally advanced SCCHN: Implications for the future
Angelicone et al. Radiotherapy in gastric cancer: Does it still play a significant role?
Koliogiannis et al. Pushing the limits in pancreatic cancer therapy
Chevallay et al. Role of surgery in the management of synchronous metastatic esophageal cancer
MA40013A (fr) Composés vegfr2/ang2